 |
canakinumab |
|---|---|
| Trade Name | Ilaris |
| Orphan Indication | Hyper-IgD syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2013-12-05 00:00:00 |
| Sponsor | Novartis Pharmaceuticals Corporation;One Health Plaza;East Hanover, New Jersey, 07936 |
| |
canakinumab |
|---|---|
| Trade Name | Ilaris |
| Orphan Indication | Hyper-IgD syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2013-12-05 00:00:00 |
| Sponsor | Novartis Pharmaceuticals Corporation;One Health Plaza;East Hanover, New Jersey, 07936 |